Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England.
Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England.
复制标题
DOI：
10.1016/j.eclinm.2021.101064
复制
发表时间：
2021-09
影响因子：
15.1
通讯作者：
COVID-19 Genomics UK (COG-UK) Consortium
中科院分区：
文献类型：
--
作者：
Mishra S;Mindermann S;Sharma M;Whittaker C;Mellan TA;Wilton T;Klapsa D;Mate R;Fritzsche M;Zambon M;Ahuja J;Howes A;Miscouridou X;Nason GP;Ratmann O;Semenova E;Leech G;Sandkühler JF;Rogers-Smith C;Vollmer M;Unwin HJT;Gal Y;Chand M;Gandy A;Martin J;Volz E;Ferguson NM;Bhatt S;Brauner JM;Flaxman S;COVID-19 Genomics UK (COG-UK) Consortium
自2020年秋季出现以来，SARS-CoV-2关注变体（VOC）B.1.1.7（WHO标签Alpha）迅速成为欧洲大部分地区的主要谱系。与此同时，全球范围内还发现了其他几种VOC。与B.1.1.7不同，这些VOC中的一些具有被认为赋予部分免疫逃逸的突变。了解这些额外的VOC何时以及如何在B.1.1.7目前占主导地位的环境中构成威胁至关重要。我们使用被动病例检测PCR数据、横断面社区感染调查、基因组监测和废水监测，研究了伦敦和其他英格兰地区非B.1.1.7谱系的流行趋势。研究期间为二零二一年一月三十一日至二零二一年五月十五日。从数据来源来看，自2021年3月下旬以来，非B.1.1.7变体的比例一直在增加。这种增加最初是由具有免疫逃逸的各种谱系驱动的。从4月中旬开始，B.1.617.2（WHO标签Delta）迅速传播，到5月下旬成为英格兰的主要变种。变异体之间竞争的结果取决于一系列广泛的因素，如内在遗传性、先前免疫的逃避、人口统计学特异性以及与非药物干预的相互作用。3月份非B.1.1.7变异的存在和上升可能是由输入和一些社区传播驱动的。非B.1.17变异体之间存在竞争，导致B.1.617.2在4月和5月成为优势变异体，并有相当大的社区传播。我们的研究结果强调，新变异的早期检测需要社区监测中的各种数据源。关于不同SARS-CoV-2谱系的高度动态组成和轨迹的持续实时信息对于未来的控制工作至关重要国家卫生研究所，药品和保健产品监管机构，DeepMind，EPSRC，EA基金计划，开放慈善事业，医学科学院比尔，梅林达盖茨基金会，帝国理工学院医疗保健NHS信托基金会，诺和诺德基金会，MRC全球传染病分析中心、Community Jameel、英国癌症研究中心、帝国理工学院COVID-19研究基金、医学研究理事会、威康桑格研究所。
Since its emergence in Autumn 2020, the SARS-CoV-2 Variant of Concern (VOC) B.1.1.7 (WHO label Alpha) rapidly became the dominant lineage across much of Europe. Simultaneously, several other VOCs were identified globally. Unlike B.1.1.7, some of these VOCs possess mutations thought to confer partial immune escape. Understanding when and how these additional VOCs pose a threat in settings where B.1.1.7 is currently dominant is vital. We examine trends in the prevalence of non-B.1.1.7 lineages in London and other English regions using passive-case detection PCR data, cross-sectional community infection surveys, genomic surveillance, and wastewater monitoring. The study period spans from 31st January 2021 to 15th May 2021. Across data sources, the percentage of non-B.1.1.7 variants has been increasing since late March 2021. This increase was initially driven by a variety of lineages with immune escape. From mid-April, B.1.617.2 (WHO label Delta) spread rapidly, becoming the dominant variant in England by late May. The outcome of competition between variants depends on a wide range of factors such as intrinsic transmissibility, evasion of prior immunity, demographic specificities and interactions with non-pharmaceutical interventions. The presence and rise of non-B.1.1.7 variants in March likely was driven by importations and some community transmission. There was competition between non-B.1.17 variants which resulted in B.1.617.2 becoming dominant in April and May with considerable community transmission. Our results underscore that early detection of new variants requires a diverse array of data sources in community surveillance. Continued real-time information on the highly dynamic composition and trajectory of different SARS-CoV-2 lineages is essential to future control efforts National Institute for Health Research, Medicines and Healthcare products Regulatory Agency, DeepMind, EPSRC, EA Funds programme, Open Philanthropy, Academy of Medical Sciences Bill,Melinda Gates Foundation, Imperial College Healthcare NHS Trust, The Novo Nordisk Foundation, MRC Centre for Global Infectious Disease Analysis, Community Jameel, Cancer Research UK, Imperial College COVID-19 Research Fund, Medical Research Council, Wellcome Sanger Institute.
登录
查看更多内容
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
DOI：
10.1016/s0140-6736(21)00183-5
发表时间：
2021-02-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Sabino EC;Buss LF;Carvalho MPS;Prete CA Jr;Crispim MAE;Fraiji NA;Pereira RHM;Parag KV;da Silva Peixoto P;Kraemer MUG;Oikawa MK;Salomon T;Cucunuba ZM;Castro MC;de Souza Santos AA;Nascimento VH;Pereira HS;Ferguson NM;Pybus OG;Kucharski A;Busch MP;Dye C;Faria NR
通讯作者：
Faria NR
影响因子：
3.9
作者：
Connor TR;Loman NJ;Thompson S;Smith A;Southgate J;Poplawski R;Bull MJ;Richardson E;Ismail M;Thompson SE;Kitchen C;Guest M;Bakke M;Sheppard SK;Pallen MJ
通讯作者：
Pallen MJ
DOI：
10.1016/s0140-6736(21)00677-2
发表时间：
2021-05-01
期刊：
Lancet (London, England)
影响因子：
--
作者：
Vasileiou E;Simpson CR;Shi T;Kerr S;Agrawal U;Akbari A;Bedston S;Beggs J;Bradley D;Chuter A;de Lusignan S;Docherty AB;Ford D;Hobbs FR;Joy M;Katikireddi SV;Marple J;McCowan C;McGagh D;McMenamin J;Moore E;Murray JL;Pan J;Ritchie L;Shah SA;Stock S;Torabi F;Tsang RS;Wood R;Woolhouse M;Robertson C;Sheikh A
通讯作者：
Sheikh A
影响因子：
64.5
作者：
Garcia-Beltran, Wilfredo F.;Lam, Evan C.;Balazs, Alejandro B.
通讯作者：
Balazs, Alejandro B.